Accessibility Menu
 
Beta Bionics logo

Beta Bionics

(NASDAQ) BBNX

Current Price$12.12
Market Cap$544.57M
Since IPO (2025)-48%
5 YearN/A
1 Year+22%
1 Month+15%

Beta Bionics Financials at a Glance

Market Cap

$544.57M

Revenue (TTM)

$110.24M

Net Income (TTM)

$66.44M

EPS (TTM)

$-1.68

P/E Ratio

-7.31

Dividend

$0.00

Beta (Volatility)

1.59 (High)

Price

$12.12

Volume

138,047

Open

$12.45

Previous Close

$12.12

Daily Range

$10.99 - $12.45

52-Week Range

$8.80 - $32.71

BBNX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Beta Bionics

Industry

Healthcare Equipment and Supplies

Employees

423

CEO

Sean Thomas Saint

Headquarters

Irvine, CA 92618, US

BBNX Financials

Key Financial Metrics (TTM)

Gross Margin

57%

Operating Margin

-70%

Net Income Margin

-60%

Return on Equity

-40%

Return on Capital

-27%

Return on Assets

-22%

Earnings Yield

-13.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$544.57M

Shares Outstanding

44.38M

Volume

138.05K

Short Interest

0.00%

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$55.54M

Operating Income

$71.68M

EBITDA

$73.20M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$219.22M

Total Debt

$12.67M

Beta Bionics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$27.63M

+56.6%

Gross Profit

$16.44M

+83.2%

Gross Margin

59.50%

N/A

Market Cap

$544.57M

N/A

Market Cap/Employee

$1.55M

N/A

Employees

352

N/A

Net Income

$21.89M

+23.6%

EBITDA

$24.27M

-34.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$192.61M

-14.2%

Accounts Receivable

$15.75M

+43.0%

Inventory

$23.73M

+50.8%

Long Term Debt

$5.07M

-6.9%

Short Term Debt

$1.84M

+20.7%

Return on Assets

-21.82%

N/A

Return on Invested Capital

-27.49%

N/A

Free Cash Flow

$25.21M

-24.1%

Operating Cash Flow

$23.83M

-19.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORICORIC Pharmaceuticals, Inc.
$10.77+1.32%
PGENPrecigen, Inc.
$3.96-0.50%
STAASTAAR Surgical Company
$24.80-0.48%
TRMLTourmaline Bio, Inc.
$47.98+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.86-0.05%
INTCIntel
$65.27-0.01%
POETPoet Technologies
$12.77+0.25%
AGPUAxe Compute
$8.75+0.79%

Questions About BBNX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.